LONG-TERM FOLLOW-UP OF IBRUTINIB MONOTHERAPY IN SYMPTOMATIC, PREVIOUSLY TREATED PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA
Long-term follow up data on the use of ibrutinib in patients with Waldenstrom macroglobulinemia (WM) indicate that this agent can produce long-term disease control in previously heavily treated patients with WM. Interestingly, the depth of response, the time to major response, and the progression-free survival were found to be impacted by the MYD88 and CXCR4 mutation status...
PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (KEYNOTE-204)
Results of the phase III KEYNOTE-2014 trial show that pembrolizumab is associated with a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with brentuximab vedotin (BV) as a treatment option for patients with relapsed or refractory classical Hodgkin lymphoma who have relapsed post-autologous HSCT or are ineligible for autologous HSCT...
IDECABTAGENE VICLEUCEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA
The B-cell maturation antigen (BCMA)–directed CAR T cell idecabtagene vicleucel (ide-vic) induced responses in a majority of heavily pre-treated patients with relapsed refractory multiple myeloma (RRMM) with a quarter of patients obtaining a minimal residual disease (MRD) negative status. Unfortunately, toxicity is an issue with almost all patients experiencing grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome (CRS)…
GENOME SEQUENCING AS AN ALTERNATIVE TO CYTOGENETIC ANALYSIS IN MYELOID CANCERS
Genomic sequencing might be a better option than cytogenetic analysis in myeloid cancer. A new study demonstrates the clinical utility of whole-genome sequencing for the genomic evaluation of patients with AML or MDS. It provides rapid and accurate genomic profiling and risk stratification and can have a greater diagnostic yield than conventional cytogenetic analysis. Especially for those with inconclusive results on cytogenetic analysis it can guide treatment decisions…
Top
